STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Vitrolife (STO:VITR) has entered into a new 3-year collaboration agreement with Cellartis AB regarding the development of new products for the culture, handling and differentiation of stem cells. The agreement extends the previous collaboration between the companies.
